Panitumumab Helps Colorectal Cancer Patients Get to Surgery
The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.
Combo Therapy Shows Modest Survival Gain, More Toxicity for Gastric Cancer
A combination of trifluridine and tipiracil showed some gains in overall survival for patients with metastatic gastric cancer or gastroesophageal junction cancer.
Nivolumab and Bevacizumab Combo Shows Activity in Ovarian Cancer
Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.
Study Moves the Needle for Melanoma Patients with Rare BRAF Mutations
BRAF and MEK inhibitors appear to have clinical activity in patients with metastatic melanoma with rare BRAF mutations.
Untangling Breast Cancer Disparities in San Francisco
A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.
Lack of Patient Understanding of PFS Points to Bigger Issues
A study showed patients seem to lack an understanding of the meaning of progression-free survival.
Timing of Palliative Care Linked to Better Lung Cancer Survival
The study found patients with lung cancer referred to palliative care earlier lived longer.
High Recurrence Score Linked with Chemotherapy Success in Breast Cancer
The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well.
Olaparib Plus Bevacizumab Prolongs Survival in Advanced Ovarian Cancer
Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.
Niraparib Shows “Impressive” Survival Improvements in Advanced Ovarian Cancer
Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.
Men with Breast Cancer Have Worse Mortality, Highlight Need for Better Awareness
A new study found men with breast cancer have higher mortality compared with women, possibly due to lack of awareness.
Addition of Metformin to TKI Therapy Delivers ‘Unusual’ Result in Lung Cancer
Researchers examined how metformin and TKI therapy did in combatting lung cancer.
Can Sorafenib be Topped in Advanced Hepatocellular Carcinoma?
New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer.
Health Savings Accounts Linked to Care Access in Cancer Survivors
Whether a cancer survivor had a health savings account (HSA) as part of their high-deductible health plan was linked to access to care.
Adolescents and Young Adults with Cancer Report Sexual Dissatisfaction
There's been much research done on how cancer of the reproductive organs affects patients' sexuality; this new study included patients with cancers outside the reproductive organs.
Considering Treatment Preferences for Advanced Lung Cancer Patients
A new study shows patients with advanced non–small-cell lung cancer have preferences on which chemotherapy side effects they'd prefer to avoid which highlights the importance of incorporating patient preferences into treatment.
What Influence Do Treatment Costs Have on Breast Cancer Surgery Preferences?
Study researchers polled 607 women who'd been previously diagnosed with breast cancer to see how recovery time, surgical complications, and cost factored into their decision to receive surgery during treatment.
Pyrotinib Combo Moves Forward in HER2-Positive Metastatic Breast Cancer
A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.
Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.
Nivolumab Combo Shows Synergistic Activity in Lymphoma
A total of 30 patients were enrolled in an expansion cohort for relapsed/refractory primary mediastinal B-cell lymphoma and received nivolumab and brentuximab vedotin.
Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?
A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
Standard Adjuvant Chemotherapy Compared to Capecitabine in Early Breast Cancer
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer recurrence-free survival.
Does Erdafitinib Show Clinical Benefit in Locally Advanced or Metastatic Urothelial Carcinoma?
Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
Timelines Matter in the Treatment of Breast Cancer
Researchers looked at the time between receiving a diagnosis and beginning chemotherapy to see if a delay in treatment impacted the overall survival in patients with breast cancer.
Measurable Residual Disease Negativity at a High in Leukemia Trial
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.
Can Immunotherapy Improve Survival in NSCLC?
A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.
Immunotherapy Failure in Pancreatic Cancer Reveals Potential Path Forward
Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.
Standardization Arrives for Neoadjuvant Trials in Melanoma
The new recommendations will help standardize neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.
The Growing Link Between Cancer and Alzheimer’s Disease
Breaking Down Chronic Pain in Cancer Survivors
This new study looked at chronic pain rates among cancer survivors, including which survivors report the highest prevalence of pain.
2 Clarke Drive Cranbury, NJ 08512